We are Anchiano Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat cancer in areas of unmet need.
Our initial program is the genetic therapy for early stage bladder cancer. Inodiftagene visteplasmid (BC-819), our most advanced investigational agent, is under development as a treatment for non-muscle-invasive bladder cancer (NMIBC).
We are located in Cambridge, MA, and in Jerusalem, and are publicly traded on the Tel Aviv Stock Exchange.
Focus on discovering and developing therapies for patients with cancer in areas of unmet need
Initial program: genetic therapy for early stage bladder cancer
Utilizes technology licensed from Hebrew University
Founded in 2004; based in Cambridge and Jerusalem
New CEO (former Harvard faculty; Ariad chief medical officer) based in Cambridge, building U.S. team and infrastructure
$45 million (end Q3 2018)
Approximate market capitalization
Publicly traded in Israel (TASE:ANCN)
$11 million (end Q3 2018)
cash, no debt
Third Quarter 2018 Financial Results (September 30, 2018)
Second Quarter 2018 Financial Results (June 30, 2018)
First Quarter 2018 Financial Results (March 31, 2018)
Consolidated Financial Statements (December 31, 2017)
Third Quarter 2017 Financial Results (September 30, 2017)
Second Quarter 2017 Financial Results (June 30, 2017)
First Quarter 2017 Financial Results (March 31, 2017)